Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska Institutet
• Collaborators: Aerocrine AB; Meda AB; Merck Sharp & Dohme Corp.; Phadia AB; Region Stockholm; Stockholm County Council, Sweden; Swedish Council for Working Life and Social Research; The Swedish Research Council; Uppsala University
• Treatments: Anti-Inflammatory Agents; Montelukast; Nitric Oxide

Criteria

Inclusion Criteria:

• Age 18-64

• Clinical diagnosis of Asthma

• Glucocorticoid treatment > 6 months.

• Verified Allergy

• Read and speak Swedish

Exclusion Criteria:

• Smoking

• Current regular treatment with long-acting beta2-agonist

• Treatment with Singulair only or in combination with glucocorticoids

• Taking part in other research study

• Pregnancy or breast-feeding

• Unstable Asthma